Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Raw Materials (2018 - 2025)

Historic Raw Materials for Protalix BioTherapeutics (PLX) over the last 11 years, with Q3 2025 value amounting to $5.0 million.

  • Protalix BioTherapeutics' Raw Materials rose 1746.82% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year increase of 1746.82%. This contributed to the annual value of $4.5 million for FY2024, which is 893.2% up from last year.
  • Latest data reveals that Protalix BioTherapeutics reported Raw Materials of $5.0 million as of Q3 2025, which was up 1746.82% from $4.4 million recorded in Q2 2025.
  • In the past 5 years, Protalix BioTherapeutics' Raw Materials ranged from a high of $5.0 million in Q3 2025 and a low of $3.0 million during Q2 2021
  • For the 5-year period, Protalix BioTherapeutics' Raw Materials averaged around $3.9 million, with its median value being $4.2 million (2023).
  • Per our database at Business Quant, Protalix BioTherapeutics' Raw Materials crashed by 2193.75% in 2021 and then surged by 4050.88% in 2023.
  • Quarter analysis of 5 years shows Protalix BioTherapeutics' Raw Materials stood at $3.2 million in 2021, then rose by 10.8% to $3.5 million in 2022, then rose by 19.04% to $4.2 million in 2023, then grew by 8.93% to $4.5 million in 2024, then grew by 9.54% to $5.0 million in 2025.
  • Its Raw Materials stands at $5.0 million for Q3 2025, versus $4.4 million for Q2 2025 and $4.5 million for Q1 2025.